UroGen Pharma (URGN) Misses Q1 EPS by 13c

UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($0.92), $0.13 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $20.25 million versus the consensus estimate of $22.5 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Canaan mined 46 bitcoin in July, holds 1,917 BTC on balance sheet
• The LGL Group (LGL) Misses Q2 EPS by 8c